Pyxis Oncology (PYXS) Cash from Operations Growth (3y) (2023 - 2025)
Pyxis Oncology (PYXS) Cash from Operations Growth (3y) (2023 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 468.28 Bn | 463.49 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 122.49 Bn | 115.24 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 70.26 Bn | 61.51 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - | - |
| 8 | Argenx Se | 55.67 Bn | 50.48 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | 34.32% |
| 10 | Pyxis Oncology | 180.71 Mn | 113.85 Mn | 8.65 Mn | 15.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15.67% |
| Sep 30, 2025 | 13.56% |
| Jun 30, 2025 | 10.04% |
| Mar 31, 2025 | 6.62% |
| Dec 31, 2024 | -16.60% |
| Sep 30, 2024 | -26.25% |
| Jun 30, 2024 | -45.03% |
| Mar 31, 2024 | -3.40% |
| Dec 31, 2023 | -68.88% |